Despicable Me 4 Dominates Chinese Box Office, Surpasses Spider-Man: Across The Spider-Verse

The lovable Minions and their leader Gru continue to captivate audiences worldwide, including in China, where Despicable Me 4 has recently achieved a significant milestone at the box office. Despite facing competition from big releases like Longlegs, Twisters, and Marvel’s Deadpool & Wolverine, the animated film has outpaced Spider-Man: Across The Spider-Verse at the Chinese box office.

This latest success has helped the Despicable Me franchise surpass an impressive $5 billion mark at the global box office. While the 2024 installment was initially expected to join the billion-dollar club, the unexpected surge of Marvel’s latest releases has made that goal challenging. However, Despicable Me 4 continues to perform strongly, keeping audiences and analysts on their toes as it inches closer to those ambitious figures.

According to a recent report, Despicable Me 4 has officially overtaken Spider-Man: Across The Spider-Verse in total earnings at the Chinese box office. Trade analyst Luiz Fernando shared that the film earned $805K on its fifth Saturday across 8,000 screenings—a 17.9% dip from the previous Saturday, when it had over 15,000 screenings. Despite the competition, the movie is still in the running to become the highest-grossing Hollywood animated film in China post-COVID.

As of now, Despicable Me 4 has raked in $50 million at the Chinese box office, edging out Spider-Man: Across The Spider-Verse‘s $49.9 million. With $185K in pre-sales for its fifth Sunday and a current 16,000 screenings, the film is projected to earn between $2 million and $2.5 million over its fifth 3-day weekend in China.

On the global stage, Despicable Me 4 has grossed $325.67 million in North America and $440.42 million internationally, including China’s $50 million. This brings its worldwide box office total to $765.1 million since its release on July 3.

Note: Box office numbers are based on estimates and various sources. These figures have not been independently verified by ent360news

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top